Creating Value by Overcoming Treatment Barriers View previous quarters - Today Latest News View all press releases 10.15.26 Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 Read More 10.14.26 Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film Read More 09.29.26 Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Read More Events View all events Upcoming Events There are no scheduled events at this time. Past Events 09.14.26 9:00 AM EDT H.C. Wainwright 28th Annual Global Investment Conference 09.09.26 3:20 PM EDT 2026 Cantor Global Healthcare Conference Fireside Chat Presentations View all presentations Corporate Presentation – September 2026 Anaphylm Human Factors and Clinical Study Supplemental Materials 1.7 MB Anaphylm™ (dibutepinephrine) Sublingual Film Complete Response Letter Supplemental Material 1.1 MB
10.15.26 Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 Read More
10.14.26 Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film Read More
09.29.26 Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Read More
